Latest Period
Q1 2026
Security Snapshot
aTYR PHARMA INC - COMMON STOCK (ATYR) Institutional Ownership
CUSIP: 002120202
13F Institutional Holders and Ownership History from Q2 2019 to Q2 2026
Institutions Reporting
111
Shares (Excl. Options)
56,055,564
Price
$0.78
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- ATYR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 56,055,564
- Total 13F value
- $43,722,358
- Portfolio coverage rank
- 0%
- Share change
- +2,155,666
- Value change
- +$1,682,623
- Number of holders
- 111
- Shares outstanding
- 98,037,765
- SEC-reported price per share
- $0.60
- Insider filing price
- $0.60
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ATYR - aTYR PHARMA INC - COMMON STOCK is tracked under CUSIP 002120202.
- 111 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 111 to 4 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $43,722,358 to $200,329.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 111 institutions filings for Q1 2026.
Security key
002120202
Latest holder period
Q1 2026
13F holders
111
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
ATYR full holder history
aTYR PHARMA INC SEC filings
aTYR PHARMA INC company facts
aTYR PHARMA INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 002120202:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ATYR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 8.7% | -19% | $5,075,172 | -$1,213,530 | 8,509,678 | -19% | Federated Hermes, Inc. | 30 Jun 2026 |
| FMR LLC | 6.1% | $5,639,105 | 5,935,900 | FMR LLC | 29 May 2026 | |||
| BlackRock, Inc. | 6.5% | $29,221,482 | 5,763,606 | BlackRock, Inc. | 30 Jun 2025 | |||
| Point72 Asset Management, L.P. | 3.2% | $9,617,297 | 2,845,354 | Point72 Asset Management, L.P. | 31 Mar 2025 |
As of 31 Mar 2026, 111 institutional investors reported holding 56,055,564 shares of aTYR PHARMA INC - COMMON STOCK (ATYR). This represents 57% of the company’s total 98,037,765 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
55%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 14,706,843 | +0.06% | 0% | $11,471,338 |
| FEDERATED HERMES, INC. | 11% | 10,509,678 | 0% | 0.01% | $8,197,549 |
| BlackRock, Inc. | 6.6% | 6,443,904 | -1.6% | 0% | $5,026,245 |
| UBS Group AG | 3.9% | 3,867,213 | +138% | 0% | $3,016,426 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 3,812,132 | 0% | 0% | $2,973,463 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,385,485 | +4.5% | 0% | $1,861,031 |
| STATE STREET CORP | 1.8% | 1,754,399 | +1.7% | 0% | $1,368,431 |
| GSA CAPITAL PARTNERS LLP | 1.7% | 1,684,586 | -36% | 0.08% | $1,314,000 |
| MILLENNIUM MANAGEMENT LLC | 1.7% | 1,641,246 | 0% | $1,280,172 | |
| MORGAN STANLEY | 1.2% | 1,225,467 | -13% | 0% | $955,865 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 1,144,565 | +152% | 0% | $892,761 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.88% | 866,744 | +13% | 0% | $676,060 |
| NORTHERN TRUST CORP | 0.73% | 711,105 | +1.3% | 0% | $554,663 |
| VANGUARD FIDUCIARY TRUST CO | 0.66% | 651,832 | 0% | 0% | $508,429 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.58% | 569,227 | 0% | 0% | $443,997 |
| AQR CAPITAL MANAGEMENT LLC | 0.51% | 496,018 | -36% | 0% | $386,894 |
| BANK OF AMERICA CORP /DE/ | 0.31% | 303,559 | +140% | 0% | $236,776 |
| GOLDMAN SACHS GROUP INC | 0.29% | 283,236 | -18% | 0% | $220,924 |
| Nuveen, LLC | 0.23% | 229,284 | +0.59% | 0% | $178,842 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.21% | 210,737 | -5% | 0% | $164,375 |
| Bank of New York Mellon Corp | 0.2% | 193,531 | -0% | 0% | $150,954 |
| GROUP ONE TRADING LLC | 0.19% | 184,014 | -3.7% | 0% | $143,531 |
| MARSHALL WACE, LLP | 0.14% | 138,118 | 0% | $107,733 | |
| XTX Topco Ltd | 0.11% | 111,423 | +40% | 0% | $86,910 |
| DEUTSCHE BANK AG\ | 0.11% | 103,326 | -14% | 0% | $80,595 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
29
Latest
Q1 2026
Rows shown
1-25 of 29
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 215,032 | $200,329 | -$30,207 | $0.60 | 4 |
| 2026 Q1 | 56,055,564 | $43,722,358 | +$1,682,623 | $0.78 | 111 |
| 2025 Q4 | 53,789,471 | $42,120,328 | -$5,233,142 | $0.78 | 84 |
| 2025 Q3 | 60,897,995 | $43,933,118 | -$49,470,950 | $0.72 | 99 |
| 2025 Q2 | 66,359,568 | $336,444,770 | +$26,875,848 | $5.07 | 109 |
| 2025 Q1 | 61,756,683 | $186,507,450 | +$18,904,946 | $3.02 | 86 |
| 2024 Q4 | 54,865,656 | $198,612,160 | +$28,523,986 | $3.62 | 77 |
| 2024 Q3 | 47,869,886 | $84,250,295 | -$378,413 | $1.76 | 55 |
| 2024 Q2 | 48,121,584 | $75,070,910 | +$8,935,546 | $1.56 | 44 |
| 2024 Q1 | 41,805,838 | $81,517,658 | +$1,482,921 | $1.95 | 56 |
| 2023 Q4 | 41,229,482 | $58,129,683 | +$3,571,040 | $1.41 | 46 |
| 2023 Q3 | 37,134,381 | $58,673,004 | +$2,049,031 | $1.58 | 41 |
| 2023 Q2 | 35,668,257 | $77,043,513 | +$2,315,570 | $2.16 | 41 |
| 2023 Q1 | 34,663,995 | $72,793,910 | +$35,335,611 | $2.10 | 37 |
| 2022 Q4 | 18,353,420 | $40,193,707 | -$2,084,056 | $2.19 | 36 |
| 2022 Q3 | 19,059,787 | $57,179,570 | +$782,338 | $3.00 | 33 |
| 2022 Q2 | 18,767,627 | $53,115,149 | -$3,104,794 | $2.83 | 34 |
| 2022 Q1 | 19,627,641 | $105,009,778 | -$6,312,765 | $5.35 | 39 |
| 2021 Q4 | 20,554,611 | $153,544,033 | +$11,326,984 | $7.47 | 46 |
| 2021 Q3 | 233,068 | $2,114,000 | -$353,397 | $7.26 | 4 |
| 2021 Q2 | 6,787,129 | $33,117,000 | +$4,918,998 | $4.88 | 23 |
| 2021 Q1 | 5,779,531 | $25,721,000 | +$251,380 | $4.45 | 19 |
| 2020 Q4 | 5,763,402 | $22,361,000 | -$366,396 | $3.88 | 19 |
| 2020 Q3 | 5,634,598 | $18,198,000 | +$467,508 | $3.23 | 20 |
| 2020 Q2 | 5,472,169 | $24,295,000 | +$1,598,388 | $4.44 | 21 |